00:01    |    
Initial credits
00:20    |    
01:52    |    
Lou Gehrig's batting average
Vitamin E treatment
03:33    |    
Course of amyotrophic lateral sclerosis (ALS)
06:04    |    
Hemispheric involvement in ALS
07:27    |    
Cells in the ventral horn
08:28    |    
Scientific advances
09:41    |    
Protein mutation
10:07    |    
Animal experiments
Removal of mutant protein from motor neurons
13:10    |    
Excitotoxicity experiment
Translational medicine
Glutamate transporter
Ceptriaxone use
18:49    |    
Neurotrophic factors
Neurotrophic subtance use
Insulin related growth factor
Growth hormone experiment
Growth factor intraventricular experiment
29:03    |    
VEGF treatment
29:49    |    
Emotional liability
Charles Darwin's publication
Emotionality in ALS example
Positive emotional control
Glutamate inhibition drug
Liability and depression
ALS patient improvement
41:40    |    
43:36    |    
ALS protein therapies
Protein aggregation
46:21    |    
Abnormal enzymatic activity
46:46    |    
Antisense oligonucleotides
Therapeutic scientific uncertainty
Intraventricular delivery of antisense oligos
Protein effects
Patient experiment
Preclinical antisense strategy
54:17    |    
ALS research team
55:41    |    
ALS experimental evolution
59:48    |    
Worlwide ALS projects
01:02:54    |    
Question and answer period
Multiple sclerosis
Importance of vitamin D
Family markers for ALS
ALS cure development sites
Alternative treatments to ALS
Have you observed SOD mutations in other related diseases?
01:13:43    |    
Final words
01:14:37    |    
Final credits




A Survey on Degenerative Diseases of the Central Nervous System

23 de marzo de 2010   | Vistas: 14 |  

About this video

Medical investigations and experimental projects have enabled scientists in many countries to obtain greater and improved data on diseases previously unknown to the medical community; that is the case of amyotrophic lateral sclerosis (ALS).  In this conference, Richard A. Smith, a specialist in this topic, shares some of the main characteristics of this medical condition and describes possible treatments, as well.  He explains its pathological traits and course in the human body through time.  Afterwards, he describes how several trial and research experiments, performed by him in different institutions applying different techniques and approaches, have offered the possibility for more treatments.  Smith explains how ALS influences behavior in patients and how this neural discovery has led to the opportunity of designing an efficient treatment that can extend the patients quality of life.  Finally, he recommends clinicians to always be aware of signs shown by the patients which might help the diagnosis and treatment.


A Survey on Degenerative Diseases of the Central Nervous Systems
Richard A. Smith

Business School Building, EN-606
Universidad Francisco Marroquín
Guatemala, March 23, 2010

New Media - UFM production.  Guatemala, May 2010
Camera: Joni Vasquez, Jorge Samayoa; digital editing: Adrián Méndez; index and synopsis: Sergio Bustamante; content reviser: Sofía Díaz; publication: Carlos Petz/Daphne Ortiz

Richard A. Smith is the medical director of the Center for Neurologic Study (CNS), principal researcher at Coordinated Clinical Research,…


Nuestra misión es la enseñanza y difusión de los principios éticos, jurídicos y económicos de una sociedad de personas libres y responsables.

Universidad Francisco Marroquín